Company intelligence / Profile preview

Adistem

Melbourne, Victoria, Australiaprweb.com ↗

Ownership: Private
Development stage: Other

Overview

Adistem has conducted early-stage clinical trials using autologous adipose-derived stromal vascular fraction in type 1 and type 2 diabetes. The company’s technologies are also used in orthopedic, cosmetic, neurologic, pulmonary, and other regenerative medicine applications. Published results highlight safety and feasibility; however, large-scale efficacy data is not publicly available[3][4].

Therapeutic areas: RheumatologyEndocrinologyOther
Modalities: Stem cell therapyPlatelet rich plasma therapyCell therapyDevice (for processing/adipose tissue and PRP)
Industry: Biotech

Drug pipeline

1 asset

autologous adipose-derived stromal vascular fraction (Adistem)

Unknown

Partnerships

Global Stem Cells Group (exclusive distributor)[6]Regenerative Medicine International (distribution partner in Asia)[2]

Beyond the preview

Go deeper on Adistem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adistem.

Explore the full profile